FDA Looks To Strengthen, Speed Drug Reviews With Flow Of Quality Data
New Approach Would Overcome Legacy Burden Of ‘Electronic Paper’
Lift the burden of paper on drug quality reviews and the pace of innovation is no longer a problem for structural engineers or couriers – or even print or electronic document rooms. The focus at the US FDA is now on enabling direct transmission and analysis of critical quality data.
You may also be interested in...
Industry complained draft guidance would have made manufacturing establishment information harder to report, not easier.
Quality oversight activity began ramping back up after the partial US government shutdown, even as EU oversight activities entered into a Brexit-related slowdown.
FDA wants feedback on a proposal to standardize the data elements of the quality and chemistry, manufacturing and controls portions of applications. The agency says such a plan will enable consistency in the content and format of CMC data submitted, thus providing a consistent look and feel for every application.